Latest Content

Daniel C. Brocks, MD, BostonSight chief medical officer, discusses a few of the company's studies, the patients they serve, and what the broader eye care community may be missing.

The free web-based tool guides eye care providers through evidence-based amblyopia diagnosis and treatment without requiring pediatric subspecialty training.

LENZ Therapeutics licenses FDA-approved presbyopia drop to Everest Medicines for Greater China; NDA under review by NMPA with approval anticipated in Q1 2027.

Researchers analyzed data from 13 randomized controlled trials involving children and adolescents with myopia.

Clark Chang, OD, MSA, MSc, FAAO, FSLS, and Susan Gromacki, OD, MS, FAAO, FSLS, provide insights into their expertise.

The strength of our referral relationships defines the quality of our patients' eye health journey.

Mile Brujic, OD, FAAO, details his experience in manufacturing his new ScleralEase device and what other ODs can learn from his experience.

Researchers from Yale School of Medicine weigh in on what everyday clinicians can take away from their findings.

Myopia management is rarely straightforward.

Yale School of Medicine researchers outline their findings and the methods of their researcher in an exclusive interview with Optometry Times.

A pilot study shows that analyzing how the cornea moves under air-puff stimulation may improve early keratoconus detection.

The university received $29.8 million through the state's Amended Fiscal Year 2026 Budget to renovate the Highway 301 building in Statesboro and create a facility to house the new program.

The product is expected to be available in stores and online at Amazon, CVS, Target and Walgreens by the end of June 2026.